- Global Operation
- Contract Manufacturing
Abiraterone is an orally active medicine which is an inhibitor of the steroidal enzyme CYP17A1. It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism. CYP17A1 is an enzyme that catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue. More specifically, abiraterone inhibits the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 and decrease serum levels of testosterone and other androgens.
Abiraterone is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
ZyteroneÂ® Tablet 250 mg : Each commercial box contains 10 tablets in Alu-Alu blister pack